To present the pharmacology and pharmacokinetics of nelarabine, 9-β-D-arabinofuranosylguanine (ara-G) and intraleukemic cellular pharmacokinetics of 9-β-D-arabinofuranosylguanine triphosphate (ara-GTP) generated from the administration of nelarabine, and clinical and safety information relative to nelarabine use in the treatment of hematologic malignancies.
DATA SOURCES:
MEDLINE (1966—December 2004) was searched using the English-language key terms 2-amino-6-methoxypurine arabinoside, 506U78, and nelarabine. Data were also obtained from published abstracts.
STUDY SELECTION AND DATA EXTRACTION:
Clinical studies evaluating the pharmacokinetics of nelarabine, ara-G, and cellular ara-GTP and use of nelarabine, alone or in combination with other agents for the treatment of hematologic malignancies, were included in this review.
DATA SYNTHESIS:
Nelarabine is the water-soluble, 6-methoxy analog of 9-β-D-ara-G. Nelarabine is readily converted to ara-G by endogenous adenosine deaminase. The half-life of nelarabine is approximately 15 minutes compared with 2–4 hours for ara-G. The clearance of ara-G is higher in children than in adults (0.312 vs 0.213 L × h−1 × kg−1). Intracellular ara-GTP elimination is slow relative to nelarabine and ara-G. In pediatric and adult patients, neurologic toxicity is dose limiting. Severe myelosuppression was not consistently observed. Major responses were seen in patients with T-cell malignancies. Patients who responded had significantly higher intracellular ara-GTP concentrations compared with those who did not respond.
CONCLUSIONS:
Nelarabine is an effective ara-G prodrug. Nelarabine has significant activity against malignant T-cells and appears to be an important addition to treatments of various leukemias.
KrenitskyTAKoszalkaGWTuttleJVRideoutJLElionGB. An enzymatic synthesis of purine-D-arabinonucleosides. Carbohydr Res1981; 97: 139–46.
2.
LambeCUAverettDRPaffMTReardonJEWilsonJGKrenitskyTA. 2-Amino-6-methoxypurine arabinoside: An agent for T-cell malignancies. Cancer Res1995; 55: 3352–6.
3.
ReistEJGoodmanL. Synthesis of 9-β-D-arabinofuranosylguanine. Biochemistry1964; 3: 15–8.
4.
JuliussonGLiliemarkJ. High complete remission rate from 2-chloro-2′-deoxyadenosine (CdA) in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol1993; 11: 679–89.
5.
HoADThalerJStryckmansPCoiffierBLucianiMSonneveldP. Pentostatin in refractory chronic lymphocytic leukemia: A phase II trial of the European organization for research and treatment of cancer. J Natl Cancer Inst1990; 82: 1416–20.
6.
KeatingMJKantarjianHTalpazMRedmanJKollerCBarlogieB. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood1989; 74: 19–25.
7.
KeatingMJO'BrienSLernerSKollerCBeranMRobertsonLE. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood1998; 92: 1165–71.
8.
HentoshPKoobRBlakleyRL. Incorporation of 2-halogeno-2′-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases a and β. J Biol Chem1990; 265: 4033–40.
9.
KufeDWMajorPPEganEMBeardsleyGP. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem1980; 255: 8997–9000.
10.
HuangPChubbSPlunkettW. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem1990; 265: 16617–25.
11.
HuangPPlunkettW. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol1995; 36: 181–8.
12.
GandhiVPlunkettWRodriguezCOJrNowakBJDuMAyresM. Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response. J Clin Oncol1998; 16: 3607–15.
13.
GandhiVPlunkettWWellerSDuMAyresMRodriguezCOR. Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics and pharmacodynamics in leukemia cells. J Clin Oncol2001; 19: 2142–52.
14.
KurtzbergJErnstTJKeatingMJGandhiVHodgeJPKisorDF. A phase I study of 2-amino-9-beta-D-arabinofuranosyl-6-methoxy-9Hpurine (506U78[Nelarabine]) administered on a consecutive five day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol (in press).
15.
PrusKLAverettDRZimmermanTP. Transport and metabolism of 9-β-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: Nitrobenzyl—thioinosine-sensitive and insensitive influx. Cancer Res1990; 50: 1817–21.
16.
RodriguezCOGandhiV. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: Incorporation into DNA is a necessary step. Cancer Res1999; 59: 4937–43.
17.
RodriguezCOMitchellBSAyresMErikssonSGandhiV. Arabinosyl-guanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res2002; 62: 3000–5.
18.
RodriguezCORLeghaJKEsteyEKeatingMJGandhiV. Pharmacological and biochemical strategies to increase accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clin Cancer Res1997; 3: 2107–13.
19.
OnoKOhashiAYamamotoAMatsukageATakahasiTSaneyoshiM. Inhibitory effects of 9-β-D-arabinofuranosylguanine 5′-triphosphate and 9-β-D-arabinofuranosyladenine 5′ triphosphate on DNA polymerases from murine cells and oncoviruses. Cancer Res1979; 39: 4673–80.
20.
GandhiVMineishiSHuangPChaomanAJYangYChenF. Cytotoxicity, metabolism, and mechanism of action of 2′, 2′-difluo-rodeoxyguanosine in Chinese hamster ovary cells. Cancer Res1995; 55: 1517–24.
21.
MitchellBSMejiaEDaddonaPEKellyWN. Purogenic immunodeficiency disease: Selective toxicity of deoxy ribonucleotides for T cells. Proc Natl Acad Sci U S A1978; 75: 5011–4.
22.
CarsonDAKayeJMatsumotoSSeegmillerJEThompsonL. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A1979; 76: 2430–3.
23.
ScharenburgJGSpaapenLJRijkersGTWadmanSKStaalGEZegersBJ. Mechanism of deoxyguanosine toxicity for human T and B lymphocytes. Adv Exp Med Biol1986; 195B: 191–9.
24.
ShewachDSDaddonaPEAshcraftEMitchellBS. Metabolism and selective cytotoxicity of 9-β-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res1985; 45: 1008–14.
25.
VerhoefVFridlandA. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res1985; 45: 3646–50.
26.
ShewachDSMitchellBS. Differential metabolism of 9-β-D-arabino-furanosylguanine in human leukemic cells. Cancer Res1989; 49: 6498–502.
27.
KisorDFPlunkettWKurtzbergJMitchellBSHodgeJPErnstT. Pharmacokinetics of nelarabine and 9-β-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol2000; 18: 995–1003.
28.
GandhiVPlunkettW. Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol1989; 38: 3551–8.
29.
GandhiVPlunkettW. Modulation arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res1988; 48: 329–34.
30.
GandhiVKemenaAKeatingMJPlunkettW. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma1993; 10: 49–56.
31.
DeAngeloDJYuDDodgeRKCoutreSEMitchelBSStoneRM. A Phase II study of 2-amino-9-β-D-arabinosyl-6methoxy-9H-purine (506U78) in patients with relapse of refractory T-lineage acute lymphoblastic leukemias (ALL) or lymphoblastic lymphoma (LBL) (abstract): CALGB Study 19801. Blood2002; 100: 742.
32.
GoyASarrisAHBleyerADuvicMMesinaODangNH. Phase II study of compound GW506U78 (Ara-G) in patients with T-cell and B-cell non-Hodgkin's lymphoma (abstract). Blood2002; 100: 4757.
33.
BergSLBlaneySMBernsteinMKurtzbergJDevidasMLampkinT. Activity of compound 506U78 in patients with refractory T-cell malignancies: A POG/CCG intergroup phase 2 study (abstract). Blood2003; 102: 792.
34.
KisorDFArumughamTAmesMHodgeJPKurtzbergJKeatingM. A dose—toxicity response model for 506U78 when administered as a one-hour infusion daily for five consecutive days in adult patients with hematologic malignancies. Pharm Res1997; 14 (suppl): s181.
